ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

GNPX Genprex Inc

2.21
0.09 (4.25%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Genprex Inc GNPX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.09 4.25% 2.21 05:29:40
개장가 저가 고가 종가 전일 종가
2.17 2.09 2.3292 2.21 2.12
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
09/04/202421:31PRNUSGenprex Collaborators Report Positive Preclinical Data on..
03/04/202421:31PRNUSGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical..
02/04/202421:31PRNUSGenprex Collaborators Publish Positive Preclinical Data with..
23/03/202405:10PRNUSGenprex Announces Closing of $6.5 Million Registered Direct..
20/03/202402:24PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
19/03/202421:36PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
12/03/202422:01PRNUSGenprex Receives Notice of Patent Grant for Korean Patent..
06/03/202423:18EDGAR2Form 8-K - Current report
06/03/202422:30PRNUSGenprex Collaborators to Present Positive Preclinical Data..
26/02/202422:45EDGAR2Form 8-K - Current report
22/02/202406:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/02/202406:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/02/202406:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/02/202404:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/02/202422:15PRNUSGenprex Expands Nonclinical Programs into New Therapeutic..
06/02/202421:30PRNUSGenprex to Present at Upcoming BIO CEO & Investor Conference
05/02/202422:15EDGAR2Form 8-K - Current report
05/02/202421:30PRNUSGenprex Announces First Patient Dosed in Phase 2a Expansion..
02/02/202421:30EDGAR2Form 8-K - Current report
31/01/202423:00EDGAR2Form 8-K - Current report
31/01/202422:42PRNUSGenprex Announces 1-for-40 Reverse Stock Split Effective..
06/01/202406:17EDGAR2Form 8-K - Current report
05/01/202421:00PRNUSGenprex Provides Business Update and Outlook for 2024
19/12/202306:35EDGAR2Form 8-K - Current report
14/12/202306:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/12/202306:44EDGAR2Form 8-K - Current report
15/11/202301:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/11/202305:19EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/11/202305:16EDGAR2Form DEF 14A - Other definitive proxy statements
01/11/202320:30PRNUSGenprex to Present at BIO-Europe 2023 Conference
24/10/202306:01EDGAR2Form PRE 14A - Other preliminary proxy statements
24/10/202305:44EDGAR2Form 8-K - Current report
20/10/202320:30PRNUSGenprex to Host a Virtual Key Opinion Leader Event on..
05/10/202301:00PRNUSGenprex to Present Data on the Use of REQORSA® for the..
26/09/202305:20EDGAR2Form 8-K - Current report
21/09/202321:30GLOBEGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation..
20/09/202321:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
09/09/202305:20EDGAR2Form 8-K - Current report
07/09/202320:30PRNUSGenprex to Present at Upcoming September Investor Conference
02/09/202305:17EDGAR2Form 8-K - Current report
22/08/202320:30PRNUSGenprex Appoints Suzanne Thornton-Jones as Senior Vice..
22/08/202306:13EDGAR2Form 8-K/A - Current report: [Amend]
22/08/202301:47EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/08/202321:30EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
10/08/202320:30PRNUSGenprex Granted FDA Orphan Drug Designation (ODD) for..
25/07/202301:17EDGAR2Form SC 13G - Statement of acquisition of beneficial..
22/07/202305:15PRNUSGenprex Announces Closing of $7.5 Million Registered Direct..
21/07/202305:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/07/202305:06EDGAR2Form 8-K - Current report
19/07/202321:00PRNUSGenprex Announces $7.5 Million Registered Direct Offering..

최근 히스토리

Delayed Upgrade Clock